History of Antibiotics: From Fluoroquinolones to Daptomycin (Part 2)

REFERENCES

• Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics: from salvarsan to cephalosporins. J Invest Surg. 2012;25:67–77.
   PubMed Web of Science ®Google Scholar
• Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–854.
   PubMed Web of Science ®Google Scholar
• Graff LR, Franklin KK, Witt L, Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. Am J Med. 2002;112:204–211.
   PubMedGoogle Scholar
• Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004). Diagn Microbiol Infect Dis. 2005;53:257–264.
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005;11(Suppl. 4):17–32.
   PubMed Web of Science ®Google Scholar
• Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003;24:284–295
   PubMed Web of Science ®Google Scholar
• Lesher GY, Froelich EJ, Gruett MD, 1,8-Naphthridine derivatives: A new class of chemotherapeutic agents. J Med Chem. 1962;5:1063–1065.
   Web of Science ®Google Scholar
• Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384–394.
   PubMed Web of Science ®Google Scholar
• Ball P, Fernald A, Tillotson G. Therapeutic advances of new fluoroquinolones. Expert Opin Investig Drugs. 1998;7:761–783.
   PubMedGoogle Scholar
• Linder JA, Huang ES, Steinman MA, Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–268.
   PubMed Web of Science ®Google Scholar
• Hooper DC. Clinical applications of quinolones. Biochim Biophys Acta. 1998;1400:45–61.
   PubMed Web of Science ®Google Scholar
• Domagala JM, Hanna LD, Heifetz CL, New structure activity relationships of the quinolone antibacterials using the target enzyme: The development and application of a DNA gyrase assay. J Med Chem. 1986;29:394–404.
   PubMed Web of Science ®Google Scholar
• Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother. 1990;26(Suppl. B):219–225.
   PubMedGoogle Scholar
• Koga H, Itoh A, Murayama S, Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3 carboxylic acids. J Med Chem. 1980;23:1358–1363.
   PubMed Web of Science ®Google Scholar
• Norrby SR, Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother. 1983;23:15–18.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Gardella A, Moellering RC Jr. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984;25: 331–335.
   PubMed Web of Science ®Google Scholar
• Sato K, Matsuura Y, Inoue M, In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother. 1982;22:548–555.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16:5–15.
   PubMed Web of Science ®Google Scholar
• Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis. 2000;30:243–254.
   PubMed Web of Science ®Google Scholar
• Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994;47:677–700.
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12–8039, a new 8-methoxyquinolone. Chemotherapy. 1996;42:410–25.
   PubMed Web of Science ®Google Scholar
• Hosaka M, Yasue T, Fukuda H, In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 1992;36:2108–2117.
   PubMed Web of Science ®Google Scholar
• Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother. 2003;51(Suppl. 1):29–35.
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao R. DNA gyrase, topoisomerase IV and the 4-quinolones. Microbiol Mol Biol Revs. 1997;61:377–392.
   PubMed Web of Science ®Google Scholar
• Hausa H, Yousef DO, Marians KJ. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase quinolone-DNA ternary complex. J Biol Chem. 1996;271:26424–26429.
   PubMedGoogle Scholar
• Marians KJ, Hiasa H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem. 1997;272:9401–9409.
   PubMed Web of Science ®Google Scholar
• Suto MJ, Domagala JM, Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity and antimicrobial activity. J Med Chem 1992;35:4745–4750.
   PubMed Web of Science ®Google Scholar
• Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S127–S135.
   PubMedGoogle Scholar
• Yang JC, Tsuji BT, Forrest A. Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med. 2007;28:586–595.
   PubMedGoogle Scholar
• Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother. 1975;8:251–261.
   PubMed Web of Science ®Google Scholar
• Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother. 1986;18(Suppl. D):21–29.
   PubMed Web of Science ®Google Scholar
• Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.
   PubMed Web of Science ®Google Scholar
• Oliphant CM, Green GM. Quinolones: A Comprehensive Review. Am Fam Phys. 2002;65:455–464.
   PubMed Web of Science ®Google Scholar
• Mandal BK. Modern treatment of typhoid fever. J Infect. 1991;22:1–4.
   PubMed Web of Science ®Google Scholar
• Bennish ML, Salam MA, Haider R, Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis. 1990;162:711–716.
   PubMed Web of Science ®Google Scholar
• Sirinavin S, Thavornnunth J, Sakchainanont B, Norfloxacin and azithromycin for treatment of nontyphoidal salmonella carriers. Clin Infect Dis. 2003;37:685–691.
   PubMed Web of Science ®Google Scholar
• DuPont HL. Quinolones in Salmonella typhi infection. Drugs. 1993;45(Suppl 3):119–124.
   PubMedGoogle Scholar
• Mattila L, Peltola H, Siitonen A, Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis. 1993;17:779–782.
   PubMedGoogle Scholar
• Olive D, Georges H, Devos P, Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis. 2011;11:66.
   PubMedGoogle Scholar
• Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769–2802.
   PubMed Web of Science ®Google Scholar
• Hameed N, Tunkel AR. Treatment of drug-resistant pneumococcal meningitis. Curr Infect Dis Rep. 2010;12:274–281.
   PubMedGoogle Scholar
• Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother. 2011;45:1439–1444.
   PubMedGoogle Scholar
• Tasso L, de Andrade C, Dalla Costa T. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Int J Antimicrob Agents. 2011;38:307–313.
   PubMedGoogle Scholar
• Goldstein EJ, Solomkin JS, Citron DM, Clinical efficacy and correlation of clinical outcomes with In Vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53:1074–1080.
   PubMed Web of Science ®Google Scholar
• Mather R, Karenchak LM, Romanowski EG, Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int J Antimicrob Agents. 2007;30:345–351.
   PubMed Web of Science ®Google Scholar
• Felmingham D, O'Hare MD, Robbins MJ, Comparative in vitro studies with 4-quinolone antimicrobials. Drugs Exp Clin Res. 1985;11:317–329.
   PubMedGoogle Scholar
• Plouffe JF. Importance of atypical pathogens of community acquired pneumonia. Clin Infect Dis. 2000;31:S35–S39.
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;36:1573–1574.
   PubMed Web of Science ®Google Scholar
• File TM Jr, Segreti J, Dunbar L, A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965–1972.
   PubMed Web of Science ®Google Scholar
• Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002;2:530–538.
   PubMed Web of Science ®Google Scholar
• Pranger AD, Alffenaar JW, Aarnoutse RE. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. Curr Pharm Des. 2011;17:2900–2930.
   PubMedGoogle Scholar
• Cremades R, Rodríguez JC, García-Pachón E, Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother. 2011;66:2281–2283.
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Owens RC Jr. New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med. 2000;21:19–32.
   PubMedGoogle Scholar
• Fisher LM, Heaton VJ. Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 2003;51:463–464.
   PubMedGoogle Scholar
• Goldstein EJC, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance of pneumococci. Clin Infect Dis. 2002;35:1505–1511.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Peterson LR, Wise R, The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721–727.
   PubMed Web of Science ®Google Scholar
• Dougherty TJ, Beaulieu D, Barrett JF. New quinolones and the impact on resistance. Drug Discov Today. 2001;6:529–536.
   PubMedGoogle Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–4960.
   PubMed Web of Science ®Google Scholar
• Cole M. "β-Lactams" as β-lactamase inhibitors. Philos. Trans. R Soc Lond B Biol Sci. 1980;289:207–223.
   PubMedGoogle Scholar
• Reading C, Cole M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977;11:852–857.
   PubMed Web of Science ®Google Scholar
• Butterworth D, Cole M, Hanscomb G, Olivanic acids, a family of beta-lactam antibiotics with beta-lactamase inhibitory properties produced by Streptornyces species. I. Detection, properties and fermentation studies. J Antibiot. 1979;32:287–294.
   PubMed Web of Science ®Google Scholar
• Kahan JS, Kahan FM, Goegelman R, Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot. 1979;32:1–12.
   PubMed Web of Science ®Google Scholar
• Miyadera T, Sugimura Y, Hashimoto T, Synthesis and in vitro activity of a new carbapenem, RS-533. J Antibiot. 1983;36:1034–1039.
   PubMed Web of Science ®Google Scholar
• Norrby SR, Alestig K, Björnegård B, Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983;23:300–307.
   PubMed Web of Science ®Google Scholar
• Edwards JR, Turner PJ, Wannop C, In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989;33:215–222.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Vreni Merriam C, Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother. 2000;44: 2389–2394.
   PubMed Web of Science ®Google Scholar
• Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs. 2001;10:1157–1166.
   PubMed Web of Science ®Google Scholar
• Iso Y, Irie T, Nishino Y, A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems. J Antibiot. 1996;49:199–209.
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical patho- gens. Antimicrob Agents Chemother. 2004;48:3136–3140.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Esposito S, Current status of newer carbapenems. Curr Med Chem. 2009;16:564–575.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, Comparative review of the carbapenems. Drugs. 2007;67:1027–1052.
   PubMed Web of Science ®Google Scholar
• Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother. 2006;58:916–929.
   PubMed Web of Science ®Google Scholar
• Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis. 2008;47(Suppl 1):S41–S51.
   Google Scholar
• Hammond ML. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother. 2004;53(Suppl 2):7–9.
   Google Scholar
• Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009;49:291–298.
   PubMed Web of Science ®Google Scholar
• Arnold RS, Thom KA, Sharma S, Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011;104:40–45.
   PubMed Web of Science ®Google Scholar
• Pillai DR, McGeer A, Low DE. New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: emerging resistance. CMAJ. 2011;183:59–64.
   PubMed Web of Science ®Google Scholar
• Dowling HF. The newer penicillins. Clin Pharmacol Therap. 1961;2:572–580.
   PubMedGoogle Scholar
• Panlilio AL, Culver DH, Gaynes RP, Methicillin resistant S. aureus in U.S. hospitals, 1975–1991. Infect Control Hosp Epidemiol 1992;13:582–586.
   PubMed Web of Science ®Google Scholar
• Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196–1199.
   PubMed Web of Science ®Google Scholar
• Doern GV, Pfaller MA, Kugler K, Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance programme. Clin Infect Dis 1998;27:764–768.
   PubMed Web of Science ®Google Scholar
• Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs. 2003;12:379–399.
   PubMed Web of Science ®Google Scholar
• Bailey EM, Rybak M, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991;35:1089–1092.
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35–S39.
   PubMed Web of Science ®Google Scholar
• McCormick MH, McGuire JM, Pittenger GE, Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot Annu. 1955–1956;3:606–611.
   Google Scholar
• Ball AP, Gray JA, Murdoch JM. Antibacterial drugs today. I. Drugs. 1975;10:1–55.
   PubMedGoogle Scholar
• Griffith RS. Vancomycin use-an historical review. J Antimicrob Chemother. 1984;14:1–5.
   PubMedGoogle Scholar
• Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42:S5–S12.
   PubMed Web of Science ®Google Scholar
• Griffith RS. Vancomycin; continued clinical studies. Antibiot Annu. 1956–1957;3:118–122.
   Google Scholar
• Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981;3:S200–S204.
   PubMedGoogle Scholar
• Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983;23:138–141.
   PubMed Web of Science ®Google Scholar
• Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42:S51–S57.
   Web of Science ®Google Scholar
• Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria–a report on the Rockefeller University workshop. N Engl J Med. 1994;17:1247–1251.
   Google Scholar
• Marrie TJ, Faulkner RS, Badley BW, Pseudomembranous colitis: isolation of two species of cytotoxic clostridia and successful treatment with vancomycin. Can Med Assoc J. 1978;119:1058–1060.
   Google Scholar
• Buzón LM, Guerrero A, Romero J, Penicillin-resistant Streptococcus pneumoniae meningitis successfully treated with vancomycin. Eur J Clin Microbiol. 1984;3:442–443.
   PubMedGoogle Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399–1408.
   PubMed Web of Science ®Google Scholar
• Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42:1303–1304.
   PubMed Web of Science ®Google Scholar
• Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis. 2001;7:183–187.
   PubMed Web of Science ®Google Scholar
• Leclerq R, Derlot E, Duval J, Plasmid mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157–161.
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Hanaki H, Ino T, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135–136.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004;39:539–545.
   PubMed Web of Science ®Google Scholar
• May, J, Shannon K, King A, Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother. 1998;42:189–197.
   PubMed Web of Science ®Google Scholar
• Denny AE, Peterson LR, Gerding DN, Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med. 1979:1026–1031.
   PubMedGoogle Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665–4672.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin. 2008;24:393–420.
   PubMed Web of Science ®Google Scholar
• Murray, BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;10:710–721.
   Google Scholar
• Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis. 2012;55(Suppl. 2):S71–S76.
   PubMed Web of Science ®Google Scholar
• McNamara DR, Steckelberg JM. Vancomycin. J Am Acad Orthop Surg. 2005;13:89–92.
   PubMedGoogle Scholar
• González C, Rubio M, Romero-Vivas J, Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999;29:1171–1177.
   PubMed Web of Science ®Google Scholar
• Recommendations for preventing the spread of vancomycin resistance. Hospital infection control practices advisory committee. Emerg Infect Dis. 1995;1:66.
   Google Scholar
• Depardieu F, Bonora MG, Reynolds PE, The vanG glycopeptide resistance operon from Enterococcus faecalis revisited. Mol Microbiol. 2003;50:931–948.
   PubMed Web of Science ®Google Scholar
• McKessar SJ, Berry AM, Bell JM, Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother. 2000;44:3224–3228.
   PubMed Web of Science ®Google Scholar
• Sahai, Jan, Healy DP, Garris R, Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis. 1989;160:876–881.
   PubMedGoogle Scholar
• Rybak, MJ, Albrecht LM, Boike SC, Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679–687.
   PubMed Web of Science ®Google Scholar
• Epstein IG, Nair KG, Boyd LJ. Cycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: a preliminary report. Antibiotic Med Clin Ther. 1955;1: 80–93.
   PubMedGoogle Scholar
• Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Des. 1996;2:175–194.
   Web of Science ®Google Scholar
• Slee AM, Wuonola MA, McRipley RJ, Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987;31:1791–1797.
   PubMed Web of Science ®Google Scholar
• Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed Engl. 2003;42:2010–2023.
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51:45–53.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Ford CW, Hutchinson DK, Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid. Expert Opin Investig Drugs. 1997;6:151–158.
   PubMedGoogle Scholar
• Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1:181–199.
   PubMedGoogle Scholar
• Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142.
   PubMed Web of Science ®Google Scholar
• Batts DH. Linezolid—a new option for treating gram-positive infections. Oncology. 2000;14:23–29.
   PubMed Web of Science ®Google Scholar
• Howe RA, Wootton M, Noel AR, Activity of AZD2563, a novel oxazolidinone, against staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob Agents Chemother. 2003;47:3651–3652.
   PubMedGoogle Scholar
• Kalia V, Miglani R, Purnapatre KP, Mode of action of ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother. 2009;53:1427–1433.
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemoth. 2009;63:713–715.
   PubMed Web of Science ®Google Scholar
• Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs. 1999;8:1195–1202.
   PubMedGoogle Scholar
• Wilson DN, Schluenzen F, Harms JM, The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA. 2008;105:13339–13344.
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrob Agents Chemother. 1998;42:3251–3255.
   PubMed Web of Science ®Google Scholar
• Patel R, Rouse MS, Piper KE, In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1999;34:119–122.
   PubMed Web of Science ®Google Scholar
• Herrmann DJ, Peppard WJ, Ledeboer NA, Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect Ther. 2008;6:825–848.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8:53–66.
   PubMed Web of Science ®Google Scholar
• Stevens, DL Herr D, Lampiris H, The Linezolid MRSA study group. Linezolid versus Vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481–1490.
   PubMed Web of Science ®Google Scholar
• Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev Anti Infect Ther. 2006;4:357–366.
   PubMedGoogle Scholar
• Mutnick AH, Enne V, Jones RN: Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother. 2003;37:769–774.
   PubMed Web of Science ®Google Scholar
• Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006;26:1784–1793.
   PubMed Web of Science ®Google Scholar
• Lam S. Linezolid-associated thrombocytopenia. Consult Pharm. 2012;27:504–508.
   PubMedGoogle Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129–1140.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Willey S, Reiszner E, In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986;30:532–535.
   PubMed Web of Science ®Google Scholar
• Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep. 2005;22:717–741.
   PubMed Web of Science ®Google Scholar
• Debono M, Barnhart M, Carrell CB, A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot. 1987;40:761–777.
   PubMed Web of Science ®Google Scholar
• Kotra, LP. Daptomycin. Curr Opin Anti-infective Investig Drugs. 2000;2:185–205.
   Google Scholar
• Tally, FP, Zeckel, M, Wasilewski, MM, Daptomycin: a novel agent for Gram-positive infections. Exp Opin Investig Drugs. 1999;8:1223–1238.
   PubMedGoogle Scholar
• Figueroa DA, Mangini E, Amodio-Groton M, Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–180.
   PubMed Web of Science ®Google Scholar
• Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010;50:S10–S15.
   PubMed Web of Science ®Google Scholar
• Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000;46:523–526.
   PubMed Web of Science ®Google Scholar
• Oleson FB Jr, Berman CL, Kirkpatrick JB, Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948–2453.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681.
   PubMed Web of Science ®Google Scholar
• Guay DR. Daptomycin: the first approved lipopeptide antimicrobial. Consult Pharm. 2004;19:614–628.
   PubMedGoogle Scholar
• Cottagnoud P. Daptomycin: a new treatment for insidious infections due to gram-positive pathogens. Swiss Med Wkly. 2008;138:93–99.
   PubMedGoogle Scholar
• Rybak MJ, Hershberger E, Moldovan T, In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin—dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44: 1062–1066.
   PubMed Web of Science ®Google Scholar
• Nagy E, Heizmann WR, Werner H. Effect of daptomycin, metronidazole and mezlocillin combinations on mixed bacterial cultures involving facultative and anaerobic bacteria. Scand J Infect Dis. 1991;23:239–245.
   PubMed Web of Science ®Google Scholar
• Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem. 2012;12:202–209.
   PubMedGoogle Scholar
• Fowler VG Jr, Boucher HW, Corey R, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665.
   PubMed Web of Science ®Google Scholar
• Mangili A, Bica I, Snydman D, Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058–1060.
   PubMed Web of Science ®Google Scholar
• Cui L, Tominaga E, Neoh HM, Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079–1082.
   PubMed Web of Science ®Google Scholar